Search research articles
Contact Us
Filters
Showing results (91-100 of 187) with videos related to
Page
of 19
Sort By:
Journal of the American Academy of Dermatology
|
May 26, 2026
Staging imaging reveals clinically significant comorbidities in primary cutaneous marginal zone lymphoma: A retrospective study
Sara Suhl, Maggie H Zhou, Alexander Kaminsky, et al.
British Journal of Haematology
|
March 2, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma
Tamer Khashab, Fredrick Hagemeister, Jorge E Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
Barbara Pro, Ranjana Advani, Pauline Brice, et al.
JCO Oncology Practice
|
December 6, 2024
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda
Bryan Valcarcel, Kerry J Savage, Brian K Link, et al.
British Journal of Haematology
|
August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
Anas Younes, Barbara Pro, Michael J Robertson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 6, 2015
Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease
Amer Beitinjaneh, Rima M Saliba, L Jeffrey Medeiros, et al.
Journal of the American Academy of Dermatology
|
January 9, 2018
Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy
Maria Estela Martinez-Escala, Alba L Posligua, Heather Wickless, et al.
Hematological Oncology
|
July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Barbara Pro, Steven M Horwitz, H Miles Prince, et al.
Leukemia & Lymphoma
|
August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
William B Pearse, Adam M Petrich, Leo I Gordon, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 187) with videos related to
Sort By:
Page
of 19
Journal of the American Academy of Dermatology
|
May 26, 2026
Staging imaging reveals clinically significant comorbidities in primary cutaneous marginal zone lymphoma: A retrospective study
Sara Suhl, Maggie H Zhou, Alexander Kaminsky, et al.
British Journal of Haematology
|
March 2, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma
Tamer Khashab, Fredrick Hagemeister, Jorge E Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
Barbara Pro, Ranjana Advani, Pauline Brice, et al.
JCO Oncology Practice
|
December 6, 2024
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda
Bryan Valcarcel, Kerry J Savage, Brian K Link, et al.
British Journal of Haematology
|
August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
Anas Younes, Barbara Pro, Michael J Robertson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 6, 2015
Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease
Amer Beitinjaneh, Rima M Saliba, L Jeffrey Medeiros, et al.
Journal of the American Academy of Dermatology
|
January 9, 2018
Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy
Maria Estela Martinez-Escala, Alba L Posligua, Heather Wickless, et al.
Hematological Oncology
|
July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Barbara Pro, Steven M Horwitz, H Miles Prince, et al.
Leukemia & Lymphoma
|
August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
William B Pearse, Adam M Petrich, Leo I Gordon, et al.
Page
of 19